Kythera Biopharmaceuticals


Kythera is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of novel prescription products for the aesthetic medicine market.  Kythera’s lead product candidate, ATX-101, is a potential first-in-class, injectable drug currently in Phase III clinical development for the reduction of submental fat.

  • Sector : Healthcare
  • Status : Public (NASDAQ: KYTH)
  • Geographic Market : U.S.
  • Investment Year : 2012
  • Investment Team : Abhijeet Lele, Ashley Friedman, Yuriy Prilutskiy